

Acinetobacter:

Selected recent publications (2015-date):

Gerson S, Lucaßen K, Wille J, Nodari CS, Stefanik D, Nowak J, Wille T, Betts JW, Roca I, Vila J, Cisneros JM, Seifert H, Higgins PG. Diversity of amino acid substitutions in PmrCAB associated with colistin resistance in clinical *Acinetobacter baumannii* isolates. *Int J Antimicrob Agents*. 2020; 55:105862

Seifert H, Stefanik D, Olesky M, Higgins PG. In-vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant *Acinetobacter baumannii*. *Int J Antimicrob Agents*. 2020; 55:105829

Cosgaya C, Ratia C, Mari-Almirall M, Rubio L, Higgins PG, Seifert H, Roca I, Vila J. In vitro and in vivo virulence potential of the emergent species of the *Acinetobacter baumannii* (Ab) group. *Front Microbiol*. 2019; 10:2429.

Opazo-Capurro A, Higgins PG, Wille J, Seifert H, Cigarroa C, González-Muñoz P, Quezada-Aguiluz M, Domínguez-Yévenes M, Bello-Toledo H, Vergara L, González-Rocha G. Genetic Features of Antarctic *Acinetobacter radioresistens* Strain A154 Harboring Multiple Antibiotic-Resistance Genes. *Front Cell Infect Microbiol*. 2019; 9:328.

Mertins S, Higgins PG, Rodríguez MG, Borlon C, Gilleman Q, Mertens P, Seifert H, Krönke M, Klimka A. Generation and selection of antibodies for a novel immunochromatographic lateral flow test to rapidly identify OXA-23-like-mediated carbapenem resistance in *Acinetobacter baumannii*. *J Med Microbiol*. 2019; 68:1021-1032.

Cerezales M, Xanthopoulou K, Wille J, Bustamante Z, Seifert H, Gallego L, Higgins PG. *Acinetobacter baumannii* analysis by core genome MLST in two hospitals in Bolivia: endemicity of international clone 7 isolates (CC25). *Int J Antimicrob Agents*. 2019; 53:844-849.

Gerson S, Betts JW, Lucaßen K, Nodari CS, Wille J, Josten M, Göttig S, Nowak J, Stefanik D, Roca I, Vila J, Cisneros JM, La Ragione RM, Seifert H, Higgins PG. Investigation of novel *pmrB* and *eptA* mutations in isogenic

Acinetobacter baumannii isolates associated with colistin resistance and increased virulence in vivo. *Antimicrob Agents Chemother.* 2019; 63. pii: e01586-18.

Klotz P, Higgins PG, Schaubmar AR, Failing K, Leidner U, Seifert H, Scheufen S, Semmler T, Ewers C. Seasonal occurrence and carbapenem susceptibility of bovine *Acinetobacter baumannii* in Germany. *Front Microbiol.* 2019; 10:272.

Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS. Antimicrobial susceptibility of *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex and *Stenotrophomonas maltophilia* clinical isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016). *Open Forum Infect Dis.* 2019; 6(Suppl 1):S34-S46.

Cerezales M, Xanthopoulou K, Ertel J, Nemec A, Bustamante Z, Seifert H, Gallego L, Higgins PG. Identification of *Acinetobacter seifertii* isolated from Bolivian hospitals. *J Med Microbiol.* 2018; 67:834-837.

Idelevich EA, Freeborn DA, Seifert H, Becker K. Comparison of tigecycline susceptibility testing methods for multidrug-resistant *Acinetobacter baumannii*. *Diagn Microbiol Infect Dis.* 2018; 91:360-362.

Higgins PG, Hrenovic J, Seifert H, Dekic S. Characterization of *Acinetobacter baumannii* from water and sludge line of secondary wastewater treatment plant. *Water Res.* 2018; 140:261-267.

Gerson S, Nowak J, Zander E, Ertel J, Wen Y, Krut O, Seifert H, Higgins PG. Diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with tigecycline resistance in *Acinetobacter baumannii*. *J Antimicrob Chemother.* 2018; 73:1501-1508.

Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible *Acinetobacter baumannii*. *Int J Antimicrob Agents.* 2018; 51:62-64.

Nowak J, Zander E, Stefanik D, Higgins PG, Roca I, Vila J, McConnell MJ, Cisneros JM, Seifert H; MagicBullet Working Group WP4. High incidence of pandrug-resistant *Acinetobacter baumannii* isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. *J Antimicrob Chemother.* 2017; 72:3277-3282.

Hujer AM, Higgins PG, Rudin SD, Buser GL, Marshall SH, Xanthopoulou K, Seifert H, Rojas L J, Domitrovic TN, Cassidy PM, Cunningham MC, Vega R, Furuno JP, Pfeiffer CD, Beldavs ZG, Wright MS, Jacobs MR, Adams MD, Bonomo RA. A nosocomial outbreak of extensively drug Resistant (XDR) *Acinetobacter baumannii* isolates containing bla(OXA-237) encoded on a plasmid. *Antimicrob Agents Chemother.* 2017; 61:e00797-17.

Wilharm G, Skiebe E, Higgins PG, Poppel MT, Blaschke U, Leser S, Heider C, Heindorf M, Brauner P, Jäckel U, Böhland K, Cuny C, Łopińska A, Kaminski P, Kasprzak M, Bochenski M, Ciebiera O, Tobółka M, Żołnierowicz KM, Siekiera J, Seifert H, Gagné S, Salcedo SP, Kaatz M, Layer F, Bender JK, Fuchs S, Semmler T, Pfeifer Y, Jerzak L. Relatedness of wildlife and livestock avian isolates of the nosocomial pathogen *Acinetobacter baumannii* to lineages spread in hospitals worldwide. *Environ Microbiol.* 2017; 19:4349-4364.

Higgins PG, Prior K, Harmsen D, Seifert H. Development and evaluation of a core genome multilocus typing scheme for whole-genome sequence-based typing of *Acinetobacter baumannii*. *PLoS One.* 2017 Jun 8;12(6):e0179228.

Marí-Almirall M, Cosgaya C, Higgins PG, Van Assche A, Telli M, Huys G, Lievens B, Seifert H, Dijkshoorn L, Roca I, Vila J. MALDI-TOF/MS identification of species from the *Acinetobacter baumannii* (Ab) group revisited: inclusion of the novel *A. seifertii* and *A. dijkshoorniae* species. *Clin Microbiol Infect.* 2017; 23: 210.e1-210.e9.

Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG Jr, Chambers HF, Bonomo RA; Antibacterial Resistance Leadership Group (ARLG).

Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics (RMDs) to identify susceptibility and resistance to carbapenems against *Acinetobacter* spp. PRIMERS III. *J Clin Microbiol.* 2017; 55:134-144.

Cosgaya C, Marí-Almirall M, Van Assche A, Fernández-Orth D, Mosqueda N, Telli M, Huys G, Higgins PG, Seifert H, Lievens B, Roca I, Vila J. *Acinetobacter* *dijkshoorniae* sp. nov., a new member of the *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex mainly recovered from clinical samples in different countries. *Int J Syst Evol Microbiol.* 2016; 66:4105-4111.

Zander E, Seifert H, Higgins PG. The effect of saline, an ambient acidic environment, and sodium-salicylate on OXA-mediated carbapenem resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2016; 60: 3415-3418.

Tomaschek F, Higgins PG, Stefanik D, Wisplinghoff H, Seifert H. Head-to-head comparison of two multi-locus sequence typing (MLST) schemes for characterization of *Acinetobacter baumannii* outbreak and sporadic isolates. *PLoS One.* 2016; 11: e0153014.

Molter G, Seifert H, Mandraka F, Kasper G, Weidmann B, Hornei B, Öhler M, Schwimmbeck P, Kröschel P, Higgins PG, Reuter S. Outbreak of carbapenem-resistant *Acinetobacter baumannii* in the intensive care unit: a multi-level strategic management approach. *J Hosp Infect.* 2016; 92:194-198.

Nowak J, Schneiders T, Seifert H, Higgins PG. The Asp20→Asn substitution in the response regulator AdeR leads to enhanced efflux activity of AdeB in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2016; 60:1085-1090.

Komp Lindgren P, Higgins PG, Seifert H, Cars O. Prevalence of hypermutators among clinical *Acinetobacter baumannii* isolates. *J Antimicrob Chemother.* 2016; 71:661-665.

Salzer HJ, Rolling T, Schmiedel S, Klupp EM, Lange C, Seifert H. Severe community-acquired bloodstream infection with *Acinetobacter ursingii* in person who injects drugs. *Emerg Infect Dis.* 2016; 22:134-137.

Garnacho-Montero J, Dimopoulos G, Poulakou G, Akova M, Cisneros JM, De Waele J, Petrosillo N, Seifert H, Timsit JF, Vila J, Zahar JR, Bassetti M. Task force on management and prevention of *Acinetobacter baumannii* infections in the ICU. *Intensive Care Med.* 2015; 41:2057-2075.

Nowak J, Seifert H, Higgins PG. Prevalence of eight resistance-nodulation-division efflux pump genes in epidemiologically characterised *Acinetobacter baumannii* of worldwide origin. *J Med Microbiol.* 2015; 64:630-635.

Staphylococcus aureus: Selected recent publications (2015-date):

Hamed K, Engelhardt M, Jones ME, Saulay M, Holland TL, Seifert H, Fowler VG Jr. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. *Future Microbiol.* 2020 Jan;15(1):35-48.

Kaasch AJ, Rommerskirchen A, Hellmich M, et al. Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection. *Trials.* 2020;21(1):175.

Rieg S, von Cube M, Kaasch A, Bonaventura B, Bothe W, Wolkewitz M, Peyerl-Hoffmann G, Deppe AC, Wahlers T, Beyersdorf F, Seifert H, Kern WV. Investigating the impact of early valve surgery on survival in Staphylococcus aureus infective endocarditis using a marginal structural model approach - results of a large prospectively evaluated cohort. *Clin Infect Dis.* 2019; 69:487-494.

Kaasch AJ, Kern WV, Joost I, Hellmich M, Seifert H, Rieg S. Effect of clinically uninfected orthopedic implants and pacemakers/aicds in low-risk Staphylococcus aureus bloodstream infection on crude mortality rate: a post hoc analysis of a large cohort study. *Open Forum Infect Dis.* 2019; 6(5):ofz170.

Nambiar K, Seifert H, Rieg S, Kern WV, Scarborough M, Gordon NC, Kim HB, Song KH, Tilley R, Gott H, Liao CH, Edgeworth J, Nsutebu E, López-Cortés LE, Morata L, Walker AS, Thwaites G, Llewelyn MJ, Kaasch AJ; International Staphylococcus aureus collaboration (ISAC) study group (with linked authorship to members in the Acknowledgements) and the ESCMID Study Group for Bloodstream Infections and Sepsis (ESGBIS). Survival following Staphylococcus aureus bloodstream infection: A prospective multinational cohort study assessing the impact of place of care. *J Infect.* 2018; 77:516-525.

Smit J, Rieg SR, Wendel AF, Kern WV, Seifert H, Schönheyder HC, Kaasch AJ. Onset of symptoms, diagnostic confirmation, and occurrence of multiple infective foci in patients with *Staphylococcus aureus* bloodstream infection: a look into the order of events and potential clinical implications. *Infection*. 2018; 46:651-658.

Joost I, Bothe W, Pausch C, Kaasch A, Lange B, Peyerl-Hoffmann G, Flüh G, Müller M, Schneider C, Seifert H, Kern WV, Beyersdorf F, Rieg S. *Staphylococcus aureus* bloodstream infection in patients with ventricular assist devices - management and outcome in a prospective bicenter cohort. *J Infect*. 2018; 77:30-37.

Joost I, Kaasch A, Pausch C, Peyerl-Hoffmann G, Schneider C, Voll RE, Seifert H, Kern WV, Rieg S. *Staphylococcus aureus* bacteremia in patients with rheumatoid arthritis - Data from the prospective INSTINCT cohort. *J Infect*. 2017; 74:575-584.

Rieg S, Joost I, Weiß V, Peyerl-Hoffmann G, Schneider C, Hellmich M, Seifert H, Kern WV, Kaasch A. Combination antimicrobial therapy in patients with *Staphylococcus aureus* bacteremia - a post hoc analysis in 964 prospectively evaluated patients. *Clin Microbiol Infect*. 2017; 23: 406.e1-406.e8.

Hos NJ, Jazmati N, Stefanik D, Hellmich M, AISael H, Kern WV, Rieg S, Wisplinghoff H, Seifert H, Kaasch AJ. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials. *J Infect*. 2017; 74:248-259.

Stewardson AJ, Allignol A, Beyersmann J, Graves N, Schumacher M, Meyer R, Tacconelli E, De Angelis G, Farina C, Pezzoli F, Bertrand X, Gbaguidi-Haore H, Edgeworth J, Tosas O, Martinez JA, Ayala-Blanco MP, Pan A, Zoncada A, Marwick CA, Nathwani D, Seifert H, Hos N, Hagel S, Pletz M, Harbarth S; TIMBER Study Group. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and *Staphylococcus aureus* in European

hospitals, 2010 and 2011: a multicenter retrospective cohort study. *Euro Surveill.* 2016; 21(33).

Eichenberger EM, Thaden JT, Sharma-Kuinkel B, Park LP, Rude TH, Ruffin F, Hos NJ, Seifert H, Rieg S, Kern WV, Lower SK, Fowler VG Jr, Kaasch AJ. Polymorphisms in fibronectin binding proteins A and B among *Staphylococcus aureus* bloodstream isolates are not associated with arthroplasty infection. *PLoS One.* 2015; 10: e0141436.

Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, Paulus U, Hellmich M, Weiß V, Jung N, Rieg S, Kern WV, Seifert H; SABATO trial group (with linked authorship to the individuals in the Acknowledgements section). Early oral switch therapy in low-risk *Staphylococcus aureus* bloodstream infection (SABATO): study protocol for a randomized controlled trial. *Trials.* 2015; 16:450.

Kaasch AJ, Jung N, Fätkenheuer G, Seifert H. Vancomycin minimum inhibitory concentration in methicillin-susceptible *Staphylococcus aureus* and mortality: more than handwaving? *Clin Infect Dis.* 2015; 60:668.

Hos NJ, Rieg S, Kern WV, Jonas D, Fowler VG Jr, Higgins PG, Seifert H, Kaasch AJ. Amino acid alterations in fibronectin binding protein A (FnBPA) and bacterial genotype are associated with cardiac device related infection in *Staphylococcus aureus* bacteraemia. *J Infect.* 2015; 70:153-159.

Other recent publications (2015-date):

Ehren K, Meißner A, Jazmati N, Wille J, Jung N, Vehreschild JJ, Hellmich M, Seifert H. Clinical impact of rapid species identification from positive blood cultures with same-day phenotypic antimicrobial susceptibility testing on the management and outcome of bloodstream infections. *Clin Infect Dis*. 2019 May 16. [Epub ahead of print]

Idelevich EA, Seifert H, Sundqvist M, Scudeller L, Amit S, Balode A, Bilozor A, Drevinek P, Tufan ZK, Koraqi A, Lamy B, Mareković I, Miciuleviciene J, Premru MM, Pascual A, Pournaras S, Saegeman V, Schönheyder HC, Schrenzel J, Strateva T, Tilley R, Wiersinga WJ, Zabicka D, Carmeli Y, Becker K; ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES). Microbiological diagnostics of bloodstream infections in Europe - An ESGBIES survey. *Clin Microbiol Infect*. 2019; 25:1399-1407.

Willmann M, Vehreschild MJGT, Biehl LM, Vogel W, Dörfel D, Hamprecht A, Seifert H, Autenrieth IB, Peter S. Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study. *BMC Biol*. 2019; 17(1):76.

Falgenhauer J, Imirzalioglu C, Falgenhauer L, Yao Y, Hauri AM, Erath B, Schwengers O, Goesmann A, Seifert H, Chakraborty T, Doijad S. Whole-Genome Sequences of Clinical *Enterobacter bugandensis* Isolates from Germany. *Microbiol Resour Announc*. 2019; 8(29).

Dimitriou V, Biehl LM, Hamprecht A, Vogel W, Dörfel D, Peter S, Schafhausen P, Rohde H, von Lilienfeld-Toal M, Klassert TE, Slickers P, Ehrlich R, Slevogt H, Christ H, Hellmich M, Farowski F, Tsakmaklis A, Higgins PG, Seifert H, Vehreschild MJGT. Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR). *J Antimicrob Chemother*. 2019; 74:2065-2074.

Biehl LM, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dörfel D, Vogel W, Häfner H, Lemmen S, Panse J, Rohde H, Klupp EM, Schafhausen P,

Imirzalioglu C, Falgenhauer L, Salmanton-García J, Stecher M, Vehreschild JJ, Seifert H, Vehreschild MJGT. Impact of single room contact precautions on hospital-acquisition and transmission of multidrug-resistant *Escherichia coli*: a prospective multicentre cohort-study in haematological and oncological wards. *Clin Microbiol Infect*. 2019; 25:1013-1020.

Rossen JWA, Dombrecht J, Vanfleteren D, De Bruyne K, van Belkum A, Rosema S, Lokate M, Bathoorn E, Reuter S, Grundmann H, Ertel J, Higgins PG, Seifert H. Epidemiological typing of *Serratia marcescens* by whole genome multi-locus sequence typing. *J Clin Microbiol*. 2019; 57. pii: e01652-18.

Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Obermann B, Knobloch JK, Feihl S, Querbach C, Gebhardt F, Mischnik A, Ihle V, Schröder W, Armean S, Peter S, Tacconelli E, Hamprecht A, Seifert H, Vehreschild MJGT, Kern WV, Gastmeier P; DZIF-ATHOS study group. Incidence of infections due to third generation cephalosporin-resistant Enterobacteriaceae - a prospective multicenter cohort study in six German university hospitals. *Antimicrob Resist Infect Control*. 2018; 7:159.

Seifert H, Blondeau J, Dowzicky MJ. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance - a report from the T.E.S.T. study. *Int J Antimicrob Agents*. 2018; 52:474–484.

Rohde AM, Wiese-Posselt M, Zweigner J, Schwab F, Mischnik A, Seifert H, Gastmeier P, Kern WV; DZIF-ATHOS Study Group. High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals. *J Antimicrob Chemother*. 2018; 73:1688-1691

Seifert H, Körber-Irrgang B, Kresken M; German Ceftolozane/Tazobactam Study Group. In-vitro activity of ceftolozane/tazobactam against *Pseudomonas aeruginosa* and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. *Int J Antimicrob Agents*. 2018; 51:227-234.

Harris PN, McNamara JF, Lye DC, Davis JS, Bernard L, Cheng AC, Doi Y, Fowler VG Jr, Kaye KS, Leibovici L, Lipman J, Llewelyn MJ, Munoz-Price S, Paul M, Peleg AY, Rodríguez-Baño J, Rogers BA, Seifert H, Thamlikitkul V, Thwaites G, Tong SY, Turnidge J, Utili R, Webb SA, Paterson DL. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. *Clin Microbiol Infect.* 2017; 23:533-541.

Mischnik A, Baumert P, Hamprecht A, Rohde AM, Peter S, Feihl S, Knobloch J, Gölz H, Kola A, Obermann B, Querbach C, Willmann M, Gebhardt F, Tacconelli E, Gastmeier P, Seifert H, Kern WV; DZIF-ATHOS Study Group. In vitro susceptibility to 19 agents other than β -lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. *J Antimicrob Chemother.* 2017; 72:1359-1363.

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *Lancet Infect Dis.* 2017; 17:153-163.

Mischnik A, Baumert P, Hamprecht A, Rohde A, Peter S, Feihl S, Knobloch J, Gölz H, Kola A, Obermann B, Querbach C, Willmann M, Gebhardt F, Tacconelli E, Gastmeier P, Seifert H, Kern WV; DZIF-ATHOS Study Group. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. *Int J Antimicrob Agents.* 2017; 49:239-242.

Mischnik A, Baumert P, Hamprecht A, Rohde A, Peter S, Feihl S, Knobloch J, Gölz H, Kola A, Obermann B, Querbach C, Willmann M, Gebhardt F, Tacconelli E, Gastmeier P, Seifert H, Kern WV; DZIF-ATHOS Study Group.

Susceptibility to penicillin derivatives among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. *Diagn Microbiol Infect Dis.* 2017; 87:71-73.

Hamprecht A, Rohde AM, Behnke M, Feihl S, Gastmeier P, Gebhardt F, Kern WV, Knobloch JK, Mischnik A, Obermann B, Querbach C, Peter S, Schneider C, Schröder W, Schwab F, Tacconelli E, Wiese-Posselt M, Wille T, Willmann M, Seifert H, Zweigner J; DZIF-ATHOS Study Group. Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. *J Antimicrob Chemother.* 2016; 71:2957-2963.

Falgenhauer L, Waezsada SE, Gwozdziński K, Ghosh H, Doijad S, Bunk B, Spröer C, Imirzalioglu C, Seifert H, Irrgang A, Fischer J, Guerra B, Käsbohrer A, Overmann J, Goesmann A, Chakraborty T. Chromosomal locations of *mcr-1* and *bla*(CTX-M-15) in fluoroquinolone-resistant *Escherichia coli* ST410. *Emerg Infect Dis.* 2016; 22: 1689-1691.

Falgenhauer L, Imirzalioglu C, Ghosh H, Gwozdziński K, Schmiedel J, Gentil K, Bauerfeind R, Kämpfer P, Seifert H, Michael GB, Schwarz S, Pfeifer Y, Werner G, Pietsch M, Roesler U, Guerra B, Fischer J, Sharp H, Käsbohrer A, Goesmann A, Hille K, Kreienbrock L, Chakraborty T. Circulation of clonal populations of fluoroquinolone-resistant CTX-M-15-producing *Escherichia coli* ST410 in humans and animals in Germany. *Int J Antimicrob Agents.* 2016; 47:457-465.

Higgins PG, Koehler D, Chan JZ, Cornely OA, Fätkenheuer G, Gillis M, Pallen MJ, Tien J, Seifert H, Vehreschild MJ, Millard AD. Draft genome sequences of nine clinical isolates of vancomycin-resistant enterococci. *Genome Announc.* 2016; 4: e00803-16.

Kresken M, Körber-Irrgang B, Biedenbach DJ, Batista N, Besard V, Cantón R, García-Castillo M, Kalka-Moll W, Pascual A, Schwarz R, Van Meensel B, Wisplinghoff H, Seifert H. Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired

urinary tract infections in three European countries. *Clin Microbiol Infect.* 2016; 22:63.e1-5.

Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. *Euro Surveill.* 2015; 20(45).

Testa R, Cantón R, Giani T, Morosini MI, Nichols WW, Seifert H, Stefanik D, Rossolini GM, Nordmann P. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. *Int J Antimicrob Agents.* 2015; 45:641-646.